Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Goldman Lab Continues Landmark Progeria Research
Uncategorized

Goldman Lab Continues Landmark Progeria Research

By medwebFeb 9, 2009
Share
Facebook Twitter Email

Goldman Lab Continues Landmark Progeria Research

Dr. Robert Goldman

Robert Goldman, PhD, Stephen Walter Ranson Professor of Cell Biology and chair of the Department of Cell and Molecular Biology, is well known for his pioneering research into the structure and function of the nuclear lamins, one subgroup of the large family of intermediate filament proteins. Recently, mutations in the gene encoding one of these proteins, nuclear lamin A, have been identified as causative factors in a wide range of human diseases. The latest tally shows that there are more than 300 mutations in the lamin A gene, leading to a wide range of diseases, including Hutchinson-Gilford Progeria Syndrome, or progeria, a rare aging disease of children that affects about 1 in 4 million.

Dr. Goldman and his coinvestigators have previously shown that progeria mutations in the lamin A gene interfere with key regulators of gene expression and the cell cycle. Now, Dr. Goldman and researchers at the Feinberg School, the Institute of Human Genetics in Munich, and the Laboratory of Supramolecular Biophysics in Hokkaido, Japan have provided new insights into the mechanisms responsible for lamin functions. Their study, “The A- and B-Type Nuclear Lamin Networks: Microdomains Involved in Chromatin Organization and Transcription,” was published in the December 15 issue of Genes and Development. In this article, Dr. Goldman et al explain that nuclear lamins normally function in the regulation of transcription and epigenetic modifications of chromatin, noting that the mechanisms responsible for these lamin functions are poorly understood. Their research demonstrates that A- and B-type lamins form separate but interacting stable meshworks in the lamina and have different mobilities in the nucleoplasm. They conclude that in normal cells, the meshworks of A-type and B-type lamins provide functionally different microenvironments whose coordinated activities finely tune the regulation of gene expression. These findings could have important implications for understanding progeria and a host of other laminopathies.

Dr. Goldman’s studies have been instrumental in developing clinical trials that offer hope to children with progeria. Dr. Goldman and others have shown that the posttranslational processing of lamin A is required for its normal functions in nuclei. One of these changes involves farnesylation of the C-terminal CAAX box, an important step in the targeting of lamin A to the membrane of the nucleus. Under normal conditions, this farnesylation site is removed to form mature lamin A so that it is properly incorporated into the nuclear lamina. However, the mutant protein, progerin, becomes permanently farnesylated and so appears to be the major causative factor in this disease. This basic knowledge has led to the rapid implementation of a drug trial employing a farnesyl transferase inhibitor, lonafarnib. Since the mutation in the gene causing progeria was only discovered in 2003, this represents an unusually rapid transition from the lab bench to the bedside and demonstrates the enormous importance of basic biomedical research. Had the information produced by the Goldman lab and several others worldwide not been available when the disease gene was discovered, implementation of drug trials would have been delayed by many years, perhaps even decades.

Full story

Share. Facebook Twitter Email

Related Posts

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Rewriting the Role of a Transcription Factor

Mar 19, 2020

Comments are closed.

Latest News

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.